Human Lyme disease vaccines: Past and future concerns

Future Microbiology

Volumn 4, Issue 4, 2009, Pages 457-469

  Nardelli, Dean T ^a   Munson, Erik L ^b   Callister, Steven M ^c   Schell, Ronald F ^a  

^a WISCONSIN STATE LABORATORY OF HYGIENE   (United States)

^b UNIVERSITY OF WISCONSIN MILWAUKEE   (United States)

^c GUNDERSEN LUTHERAN MEDICAL CENTER   (United States)

Author keywords

Borrelia burgdorferi; Lyme disease; Lyme vaccine; OspA; OspC

Indexed keywords

BACTERIAL ANTIGEN; BACTERIAL VACCINE; LYME DISEASE VACCINE; OUTER SURFACE PROTEIN A VACCINE; OUTER SURFACE PROTEIN C; OUTER SURFACE PROTEIN C VACCINE; PLACEBO; UNCLASSIFIED DRUG;

ANTIBODY TITER; ARTHRITIS; BACTERIAL GROWTH; BACTERIAL VIRULENCE; BORRELIA BURGDORFERI; CLINICAL TRIAL; COMPLEMENT FACTOR; DOWN REGULATION; DRUG EFFICACY; DRUG SAFETY; GROWTH INHIBITION; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOREACTIVITY; INFECTIOUS ARTHRITIS; LYME DISEASE; NEUROLOGIC DISEASE; NONHUMAN; PRIORITY JOURNAL; PROTEIN TARGETING; REVIEW; TICK BORNE DISEASE; ENDEMIC DISEASE; HISTORY; IMMUNOLOGY; MEDICAL RESEARCH;

BORRELIA BURGDORFERI;

BIOMEDICAL RESEARCH; ENDEMIC DISEASES; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; LYME DISEASE; LYME DISEASE VACCINES;

EID: 66949128690     PISSN: 17460913     EISSN: None     Source Type: Journal    
DOI: 10.2217/fmb.09.17     Document Type: Review

References (125)

1. Steere AC: Lyme disease. N. Engl. J. Med. 345, 115-125 (2001).
2. Rudenko N, Golovchenko M, Mokrácek A et al.: Detection of Borrelia bissettii in cardiac valve tissue of a patient with endocarditis and aortic valve stenosis in the Czech Republic. J. Clin. Microbiol. 46, 3540-3543 (2008).
3. da Franca I, Santos L, Mesquita T et al.: Lyme borreliosis in Portugal caused by Borrelia lusitaniae? Clinical report on the first patient with a positive skin isolate. Wein. Klin. Wochenschr. 117, 429-432 (2005).
4. Diza E, Papa A, Vezyri E, Tsounis S, Milonas I, Antoniadis A: Borrelia valaisiana in cerebrospinal fluid. Emerg. Infect. Dis. 10, 1692-1693 (2004).
5. Wang G, van Dam AP, Dankert J: Phenotypic and genetic characterization of a novel Borrelia burgdorferi sensu lato isolate from a patient with Lyme borreliosis. J. Clin. Microbiol. 37, 3025-3028 (1999).
6. Wang I-N, Dykhuizen DE, Qiu W, Dunn JJ, Bosler EM, Luft BJ: Genetic diversity of ospC in a local population of Borrelia burgdorferi sensu stricto. Genetics. 151, 15-30 (1999).
7. Goldings EA, Jericho J: Lyme disease. Clin. Rheum. Dis. 12, 343-367 (1986).
8. Murphree Bacon R, Kugeler KJ, Mead PS: Surveillance for Lyme disease-United States, 1992-2006. Morb. Mortal. Wkly Rep. 57(SS10), 1-9 (2008).
9. Smith R, Takkinen J, Editorial Team: Lyme borreliosis: Europe-wide coordinated surveillance and action needed? Euro. Surveill. 11(6), E060622.1 (2006).
10. Johnson RC, Kodner C, Russell M: Passive immunization of hamsters against experimental infection with the Lyme disease spirochete. Infect. Immun. 53, 713-714 (1986).
11. Johnson RC, Kodner C, Russell M: Active immunization of hamsters against experimental infection with Borrelia burgdorferi. Infect. Immun. 54, 897-898 (1986).
12. Schmitz JL, Schell RF, Hejka AG, England DM: Passive-immunization prevents induction of Lyme arthritis in LSH hamsters. Infect. Immun. 58, 144-148 (1990).
13. Schmitz JL, Schell RF, Lovrich SD, Callister SM, Coe JE: Characterization of the protective antibody response to Borrelia burgdorferi in experimentally infected LSH hamsters. Infect. Immun. 59, 1916-1921 (1991).
14. Barbour AG, Tessier SL, Todd WJ: Lyme disease spirochetes and Ixodid tick spirochetes share a common surface antigenic determinant defined by a monoclonal antibody. Infect. Immun. 41, 795-804 (1983).
15. Fikrig E, Barthold SW, Kantor FS, Flavell RA: Protection of mice against the Lyme disease agent by immunizing with recombinant OspA. Science 250, 553-556 (1990).
16. Simon MM, Schaible UE, Kramer MD et al.: Recombinant outer surface protein A from Borrelia burgdorferi induces antibodies protective against spirochetal infection in mice. J. Infect. Dis. 164, 123-132 (1991).
17. Callister SM, Schell RF, Case KL, Lovrich SD, Day SP: Characterization of the borreliacidal antibody response to Borrelia burgdorferi in humans: a serodiagnostic test. J. Infect. Dis. 167, 158-164 (1993).
18. Fikrig E, Bockenstedt LK, Barthold SW et al.: Sera from patients with chronic Lyme disease protect mice from Lyme borreliosis. J. Infect. Dis. 169, 568-574 (1994).
19. Schaible UE, Kramer MD, Eichmann K, Modolell M, Museteanu C, Simon MM: Monoclonal antibodies specific for the outer surface protein A (OspA) of Borrelia burgdorferi prevent Lyme borreliosis in severe combined immunodeficiency (scid) mice. Proc. Natl Acad. Sci. USA 87, 3768-3772 (1990).
20. Fikrig E, Barthold SW, Kantor FS, Flavell RA: Long-term protection of mice from Lyme disease by vaccination with OspA. Infect. Immun. 60, 773-777 (1992).
21. Fikrig E, Telford SR III, Barthold SW, Kantor FS, Spielman A, Flavell RA: Elimination of Borrelia burgdorferi from vector ticks feeding on OspA-immunized mice. Proc. Natl Acad. Sci. USA 89, 5418-5421 (1992).
22. Telford SR III, Fikrig E, Barthold SW, Brunet LR, Spielman A, Flavell RA: Protection against antigenically variable Borrelia burgdorferi conferred by recombinant vaccines. J. Exp. Med. 178, 755-758 (1993).
23. Lovrich SD, Callister SM, DuChateau BK et al.: Abilities of OspA proteins from different seroprotective groups of Borrelia burgdorferi to protect hamsters from infection. Infect. Immun. 63, 2113-2119 (1995).
24. Chang Y-F, Appel MJG, Jacobson RH et al.: Recombinant OspA protects dogs against infection and disease caused by Borrelia burgdorferi. Infect. Immun. 63, 3543-3549 (1995).
25. Coughlin RT, Fish D, Mather TN, Ma J, Pavia C, Bulger P: Protection of dogs from Lyme disease with a vaccine containing outer surface protein (Osp) A, OspB, and the saponin adjuvant QS21. J. Infect. Dis. 171, 1049-1052 (1995).
26. Ma J, Hine PM, Clough ER et al.: Safety, efficacy, and immunogenicity of a recombinant Osp subunit canine Lyme disease vaccine. Vaccine 14, 1366-1374 (1996).
27. Philipp MT, Lobet Y, Bohm RP Jr et al.: The outer surface protein A (OspA) vaccine against Lyme disease: efficacy in the rhesus monkey. Vaccine 15, 1872-1887 (1997).
28. Steere AC, Sikand VK, Meurice F et al.: Vaccination against Lyme disease with recombinant Borrelia burgdorferi outer-surface lipoprotein A with adjuvant. N. Engl. J. Med. 339, 209-215 (1998).
29. Sears JE, Fikrig E, Nakagawa TY et al.: Molecular mapping of OspA-mediated immunity against Borrelia burgdorferi, the agent of Lyme disease. J. Immunol. 147, 1995-2000 (1991).
30. Johnson BJB, Sviat SL, Happ CM et al.: Incomplete protection of hamsters vaccinated with unlipidated OspA from Borrelia burgdorferi infection is associated with low levels of antibody to an epitope defined by mAb LA-2. Vaccine 13, 1086-1094 (1995).
31. Kurtenbach K, Dizij A, Voet P, Hauser P, Simon MM: Vaccination of natural reservoir hosts with recombinant lapidated OspA induces a transmission-blocking immunity against Lyme disease spirochaetes associated with high levels of LA-22 equivalent antibodies. Vaccine 15, 1670-1674 (1997).
32. Sigal LH, Zahradnik JM, Lavin P et al.: A vaccine consisting of recombinant Borrelia burgdorferi outer-surface protein A to prevent Lyme disease. N. Engl. J. Med. 339, 216-222 (1998).
33. Luger S: Immunization against Lyme disease [Letter]. N. Engl. J. Med. 339, 1637-1638 (1998).
34. Steere AC, Parenti DL, Krause DS: Immunization against Lyme disease [Letter]. N. Engl. J. Med. 339, 1638-1639 (1998).
35. Hayes EB, Dennis DT: Immunization against Lyme disease [Letter]. N. Engl. J. Med. 339, 1637-1638 (1998).
36. Padilla ML, Callister SM, Schell RF et al.: Characterization of the protective borreliacidal antibody response in humans and hamsters after vaccination with a Borrelia burgdorferi outer surface protein A vaccine. J. Infect. Dis. 174, 739-746 (1996).
37. Luke CJ, Marshall MA, Zahradnik JM, Bybel M, Menefee BE, Barbour AG: Growth-inhibiting antibody responses of humans vaccinated with recombinant outer surface protein A or infected with Borrelia burgdorferi or both. J. Infect. Dis. 181, 1062-1068 (2000).
38. Keller D, Koster FT, Marks DH, Hosbach P, Erdile LF, Mays JP: Safety and immunogenicity of a recombinant outer surface protein A Lyme vaccine. JAMA 217, 1764-1768 (1994).
39. de Silva AM, Telford SR III, Bruner LR, Barthold SW, Fikrig E: Borrelia burgdorferi OspA is an arthropod-specific transmission-blocking Lyme disease vaccine. J. Exp. Med. 183, 271-275 (1996).
40. de Silva AM, Zeidner NS, Zhang Y, Dolan MC, Piesman J, Fikrig E: Influence of outer surface protein A antibody on Borrelia burgdorferi within feeding ticks. Infect. Immun. 67, 30-35 (1999).
41. Ribeiro MC: Ixodes dammini: salivary anticomplementary activity. Exp. Parisitol. 64, 347-353 (1987).
42. Valenzuela JG, Charlab R, Mather TN, Ribeiro JM: Purification, cloning, and expression of a novel salivary anticomplement protein from the tick, Ixodes scapularis. J. Biol. Chem. 275, 18717-18723 (2000).
43. Alitalo A, Meri T, Rämö L et al.: Complement evasion by Borrelia burgdorferi: serum-resistant strains promote C3b inactivation. Infect. Immun. 69, 3685-3691 (2001).
44. Alitalo A, Meri T, Lankinen H et al.: Complement inhibitory factor H binding to Lyme disease spirochetes is mediated by inducible expression of multiple plasmid-encoded outer surface protein E paralogs. J. Immunol. 169, 3847-3853 (2002).
45. Pausa M, Pellis V, Cinco M et al.: Serum-resistent strains of Borrelia burgdorferi evade complement-mediated killing by expressing a CD59-like-complement inhibitory molecule. J. Immunol. 170, 3214-3222 (2003).
46. Schmitz JL, Lovrich SD, Callister SM, Schell RF: Depletion of complement and effects on passive transfer of resistance to infection with Borrelia burgdorferi. Infect. Immun. 59, 3815-3818 (1991).
47. Munson EL, DuChateau BK, Jobe DA, Lovrich SD, Callister SM, Schell RF: Production of borreliacidal antibody to outer surface protein A in vitro and modulation by interleukin-4. Infect. Immun. 68, 5496-5501 (2000).
48. Rathinavelu S, Broadwater A, de Silva A: Does host complement kill Borrelia burgdorferi within ticks? Infect. Immun. 71, 822-829 (2003).
49. Nowling JM, Philipp MT: Killing of Borrelia burgdorferi by antibody elicited by OspA vaccine is inefficient in the absence of complement. Infect. Immun. 67, 443-445 (1999).
50. Solé M, Bamar C, Indest K et al.: Borrelia burgdorferi escape mutants that survive in the presence of antiserum to the OspA vaccine axe killed when complement is also present. Infect. Immun. 66, 2540-2546 (1998).
51. Schwan TG, Piesman J, Golde WT, Dolan MC, Rosa PA: Induction of an outer surface protein an Borrelia burgdorferi during tick feeding. Proc. Natl Acad. Sci. USA 92, 2909-2913 (1995).
52. Schwan TG, Kime KK, Schrumpf ME, Coe JE, Simpson WJ: Antibody response in white-footed mice (Peromyscus leucopus) experimentally infected with the Lyme disease spirochete (Borrelia burgdorferi). Infect. Immun. 57, 3445-3451 (1989).
53. Golde WT, Kappel KJ, Dequesne G et al.: Tick transmission of Borrelia burgdorferi to inbred strains of mice induces an antibody response to P39 but not to outer surface protein A. Infect. Immun. 62, 2625-2627 (1994).
54. Roehrig JT, Piesman J, Hunt AR, Keen MG, Happ CM, Johnson BJB: The hamster immune response to tick-transmitted Borrelia burgdorferi differs from the response to needle-inoculated, cultured organisms. J. Immunol. 149, 3648-3653 (1992).
55. Schaible UE, Gern L, Wallich R, Kramer MD, Prester M, Simon MM: Distinct patterns of protective antibodies are generated against Borrelia burgdorferi in mice experimentally inoculated with high and low doses of antigen. Immunol. Lett. 36, 219-226 (1993).
56. Barthold SW, Levy SA, Fikrig E, Bockenstedt LK, Smith AL: Serologic responses of dogs naturally exposed to or vaccinated against Borrelia burgdorferi infection. J. Am. Vet. Med. Assoc. 207, 1435-1440 (1995).
57. Schutzer SE, Coyle PK, Dunn JJ, Luft BJ,. Brunner M: Early and specific antibody responses to OspA in Lyme disease. J. Clin. Invest. 94, 454-457 (1994).
58. Kalish RA, Leong JM, Steere AC: Early and late antibody responses to full-length and truncated constructs of outer surface protein A of Borrelia burgdorferi in Lyme disease. Infect. Immun. 63, 2228-2235 (1995).
59. Dressler F, Whalen JA, Reinhardt BN, Steere AC: Western blotting in the serodiagnosis of Lyme disease. J. Infect. Dis. 167, 392-400 (1993).
60. Engstrom SM, Shoop E, Johnson RC: Immunoblot interpretation criteria for serodiagnosis of early Lyme disease. J. Clin. Microbiol. 33, 419-427 (1995).
61. Aguero-Rosenfeld ME, Nowakowski J, Bittker S, Cooper D, Nadelman RB, Wormser GP: Evolution of the serologic response to Borrelia burgdorferi in treated patients with culture-confirmed erythema migrans. J. Clin. Microbiol. 34, 1-9 (1996).
62. Shang ES, Champion CI, Wu X-Y et al.: Comparison of protection in rabbits against host-adapted and cultivated Borrelia burgdorferi following infection-derived immunity or immunization with outer membrane vesicles or outer surface protein A. Infect. Immun. 68, 4189-4199 (2000).
63. Battisti JM, Bono JL, Rosa PA, Schrumpf ME, Schwan TG, Policastro PF: Outer surface protein A protects Lyme disease spirochetes from acquired host immunity in the tick vector. Infect. Immun. 76, 5228-5237 (2008).
64. Steere AC, Glickstein L: Elucidation of Lyme arthritis. Nat. Rev. Immunol. 4, 143-152 (2004).
65. Rosé CD, Fawcett PT, Gibney KM: Arthritis following recombinant outer surface protein A vaccination for Lyme disease. J. Rheumatol. 28, 2555-2557 (2001).
66. Latov N, Wu AT, Chin RL, Sander HW, Alaedini A, Brannagan TH III: Neuropathy and cognitive impairment following vaccination with the OspA protein of Borrelia burgdorferi. J. Peripher. Nerv. Syst. 9, 165-167 (2004).
67. Steere AC, Dwyer E, Winchester R: Association of chronic Lyme arthritis with HLA-DR4 and HLA-DR2 alleles. N. Engl. J. Med. 323, 219-223 (1990).
68. Kalish RA, Leong JM, Steere AC: Association of treatment-resistant chronic Lyme arthritis with HLA-DR4 and antibody reactivity to OspA and OspB of Borrelia burgdorferi. Infect. Immun. 61, 2774-2779 (1993).
69. Akin E, McHugh GL, Flavell RA, Fikrig E, Steere AC: The immunoglobulin (IgG) antibody response to OspA and OspB correlates with severe and prolonged Lyme arthritis and the IgG response to P35 correlates with mild and brief arthritis. Infect. Immun. 67, 173-181 (1999).
70. Yoshinari NH, Reinhardt BN, Steere AC: T cell responses to polypeptide fractions of Borrelia burgdorferi in patients with Lyme arthritis. Arthritis Rheum. 34, 707-713 (1991).
71. Shanafelt MC, Hindersson P, Soderberg C et al.: T cell and antibody reactivity with the Borrelia burgdorferi 60-kDa heat shock protein in Lyme arthritis. J. Immunol. 146, 3985-3992 (1991).
72. Kamradt T, Lengl-Janssen B, Strauss AF, Bansal G, Steere AC: Dominant recognition of a Borrelia burgdorferi outer surface protein A peptide by T-helper cells in patients with treatment-resistant Lyme arthritis. Infect. Immun. 64, 1284-1289 (1996).
73. Chen J, Field JA, Glickstein L, Molloy PJ, Huber BT, Steere AC: Association of antibiotic treatment-resistant Lyme arthritis with T-cell responses to dominant epitopes of outer surface protein A of Borrelia burgdorferi. Arthritis Rheum. 42, 1813-1822 (1999).
74. Lengl-Janssen B, Strauss AF, Steere AC, Kamradt T: The T-helper cell response in Lyme arthritis: differential recognition of Borrelia burgdorferi outer surface protein A in patients with treatment-resistant or treatment-responsive Lyme arthritis. J. Exp. Med. 180, 2069-2078 (1994).
75. Gross DM, Steere AC, Huber BT: T-helper 1 response is dominant and localized to the synovial fluid in patients with Lyme arthritis. J. Immunol. 160, 1022-1028 (1998).
76. Winchester R, Dwyer E, Rose S: The genetic basis of rheumatoid arthritis. The shared epitope hypothesis. Rheum. Dis. Clin. North Am. 18, 761-783 (1992).
77. Steere AC, Falk B, Drouin EE, Baxter-Lowe LA, Hammer J, Nepom GT: Binding of outer surface protein A and human lymphocyte function-associated antigen 1 peptides to HLA-DR molecules associated with antibiotic treatment-resistant Lyme arthritis. Arthritis Rheum. 48, 534-540 (2003).
78. Steere AC, Klitz W, Djouin EE et al.: Antibiotic-refractory Lyme arthritis is associated with HLA-DR molecules that bind a Borrelia burgdorferi peptide. J. Exp. Med. 203, 961-971 (2006).
79. Gross DM, Forsthuber T, Tary-Lehmann M et al.: Identification of LFA-1 as a candidate autoantigen in treatment-resistant Lyme arthritis. Science 281, 703-706 (1998).
80. L is a partial agonist for outer surface protein A-reactive T cells. J. Immunol. 166, 5286-5291 (2001).
81. Lathrop SL, Ball R, Haber P et al.: Adverse event reports following vaccination for Lyme disease: December 1998 - July 2000. Vaccine 20, 1603-1608 (2002).
82. Lim LCL, England DM, DuChateau BK et al.: Development of destructive arthritis in vaccinated hamsters challenged with Borrelia burgdorferi. Infect. Immun. 62, 2825-2833 (1994).
83. Lim LC, England DM, DuChateau BK, Glowacki NJ, Schell RF: Borrelia burgdorferi-specific T lymphocytes induce severe destructive Lyme arthritis. Infect. Immun. 63, 1400-1408 (1995).
84. Christopherson JA, Munson EL, England DM et al.: Destructive arthritis in vaccinated interferon γ-deficient mice challenged with Borrelia burgdorferi: modulation by tumor necrosis factor α. Clin. Diagn. Lab. Immunol. 10, 44-52 (2003).
85. Burchill MA, Nardelli DT, England DM et al.: Inhibition of interleukin-17 prevents development of arthritis in vaccinated mice challenged with Borrelia burgdorferi. Infect. Immun. 71, 3437-3442 (2003).
86. Munson EL, DeCoster DJ, Nardelli DT, England DM, Callister SM, Schell RF: Neutralization of γ interferon augments borreliacidal antibody production and severe desctructive Lyme arthritis in C3H/HeJ mice. Clin. Diagn. Lab. Immunol. 11, 35-41 (2004).
87. Nardelli DT, Luk KHK, Kotloski NJ et al.: Role of IL-17, transforming growth factor-β, and IL-6 in the development of arthritis and production of antiouter surface protein A borreliacidal antibodies in Borrelia-vaccinated and -challenged mice. FEMS Immunol. Med. Microbiol. 53, 265-274 (2008).
88. Croke CL, Munson EL, Lovrich SD et al.: Occurrence of severe destructive Lyme arthritis in hamsters vaccinated with outer surface protein A and challenged with Borrelia burgdorferi. Infect. Immun. 68, 658-663 (2000).
89. Willett TA, Meyer AL, Brown EL, Huber BT: An effective second-generation outer surface protein A-derived Lyme vaccine that eliminates a potentially autoreactive T-cell epitope. Proc. Natl Acad. Sci. USA 101, 1303-1308 (2004).
90. Schwah TG: Temporal regulation of outer surface proteins of the Lyme-disease spirochaete Borrelia burgdorferi. Biochem. Soc. Trans. 31, 108-112 (2003).
91. Stevenson B, Schwan TG, Rosa PA: Temperature-related differential expression of antigens in the Lyme disease spirochete, Borrelia burgdorferi. Infect. Immun. 63, 4535-4539 (1995).
92. Srivastava SY, de Silva AM: Reciprocal expression of ospA and ospC in single cells of Borrelia burgdorferi. J. Bacteriol. 190, 3429-3433 (2008).
93. Schwan TG, Piesman J: Temporal changes in outer surface proteins A and C of the Lyme-associated spirochete, Borrelia burgdorferi, during the chain of infection in ticks and mice. J. Clin. Microbiol. 38, 382-388 (2000).
94. Montgomery RR, Malawista SE, Feen KJM, Bockenstedt LK: Direct demonstration of antigenic substitution of Borrelia burgdorferi ex vivo: exploration of the paradox of the early immune response to outer surface proteins A and C in Lyme disease. J. Exp. Med. 183, 261-269 (1996).
95. Grimm D, Tilly K, Byram R et al.: Outer-surface protein C of the Lyme disease spirochete: a protein induced in ticks for infection of mammals. Proc. Natl Acad. Sci. USA 101, 3142-3147 (2004).
96. Wilske B, Preac-Mursic V, Schierz G, Busch KV: Immunochemical and immunological analysis of European Borrelia burgdorferi strains. Zentralbl. Bakteriol. Mikrobiol. Hyg. 263, 92-102 (1986).
97. Padula SJ, Sampieri A, Dias F, Szczepanski A, Ryan RW: Molecular characterization and expression of p23 (OspC) from a North American strain of Borrelia burgdorferi. Infect. Immun. 61, 5097-5105 (1993).
98. Fung BP, McHugh GL, Leong JM, Steere AC: Humoral immune response to outer surface protein C of Borrelia burgdorferi in Lyme disease: role of the immunoglobulin M response in the serodiagnosis of early infection. Infect. Immun. 62, 3213-3221 (1994).
99. Preac-Mursic V, Wilske B, Patsouris E et al.: Active immunization with pC protein of Borrelia burgdorferi protects gerbils against B. burgdorferi infection. Infection 20, 342-349 (1992).
100. Probert WS, LeFebvre RB: Protection of C3H/HeN mice from challenge with Borrelia burgdorferi through active immunization with OspA, OspB, or OspC, but not with OspD or the 83-kilodalton antigen. Infect. Immun. 62, 1920-1926 (1994).
101. Gilmore RD Jr, Kappel KJ, Dolan MC, Burkot TR, Johnson BJB: Outer surface protein C (OspC), but not P39, is a protective immunogen against a tick-transmitted Borrelia burgdorferi challenge: evidence for a conformational protective epitope in OspC. Infect. Immun. 64, 2234-2239 (1996).
102. Zhong W, Gern L, Stehle T et al.: Resolution of experimental and tick-borne Borrelia burgdorferi infection in mice by passive, but not active immunization using recombinant OspC. Eur. J. Immunol. 29, 946-957 (1999).
103. Mbow ML, Gilmore RD Jr, Titus RG: An OspC-specific monoclonal antibody passively protects mice from tick-transmitted infection by Borrelia burgdorferi B31. Infect. Immun. 67, 5470-5472 (1999).
104. Gilmore RD Jr, Piesman J: Inhibition of Borrelia burgdorferi migration from the midgut to the salivary glands following feeding by ticks on OspC-immunized mice. Infect. Immun. 68, 411-414 (2000).
105. Rousselle JC, Callister SM, Schell RF et al.: Borreliacidal antibody production against outer surface protein C of Borrelia burgdorferi. J. Infect. Dis. 178, 733-741 (1998).
106. Callister SM, Jobe DA, Schell RF, Pavia CS, Lovrich SD: Sensitivity and specificity of the borreliacidal antibody test during early Lyme disease: a gold standard? Clin. Diagn. Lab. Immunol 3, 399-402 (1996).
107. Gilmore RD Jr, Bacon RM, Carpio AM, Piesman J, Dolan MC, Mbow ML: Inability of outer-surface protein C (OspC)-primed mice to elicit a protective anamnestic immune response to a tick-transmitted challenge of Borrelia burgdorferi. J. Med. Microbiol. 52, 551-556 (2003).
108. Liang FT, Jacobs MB, Bowers LC, Phillip MT: An immune evasion mechanism for spirochetal persistence in Lyme borreliosis. J. Exp. Med. 195, 415-422 (2002).
109. Remington MC, Munson EL, Callister SM et al.: Interleukin-6 enhances production of anti-OspC immunoglobulin G2b borreliacidal antibody. Infect. Immun. 69, 4268-4275 (2001).
110. Wilske B, Preac-Mursic V, Jauris S et al.: Immunological and molecular polymorphisms of OspC, an immunodominant major outer surface protein of Borrelia burgdorferi. Infect. Immun. 61, 2182-2191 (1993).
111. Theisen M, Frederiksen B, Lebech A-M, Vuust J, Hansen K: Polymorphism in ospC gene of Borrelia burgdorferi and immunoreactivity of OspC protein: implications for taxonomy and for use of OspC protein as a diagnostic antigen. J. Clin. Microbiol. 31, 2570-2576 (1993).
112. Wilske B, Jauris-Heipke S, Lobentanzer R et al.: Phenotypic analysis of outer surface protein C (OspC) of Borrelia burgdorferi sensu lato by monoclonal antibodies: relationship to genospecies and OspA serotype. J. Clin. Microbiol. 33, 103-109 (1995).
113. Earnhart CG, Marconi RT: OspC phylogenetic analyses support the feasibility of a broadly protective polyvalent chimeric Lyme disease vaccine. Clin. Vaccine Immunol. 14, 628-634 (2007).
114. Probert WS, Crawford M, Cadiz RB, LeFebvre RB: Immunization with outer surface protein (Osp) A, but not OspC, provides cross-protection of mice challenged with North American isolates of Borrelia burgdorferi. J. Infect. Dis. 175, 400-405 (1997).
115. Bockenstedt LK, Hodzic E, Feng S et al.: Borrelia burgdorferi strain-specific OspC-mediated immunity in mice. Infect. Immun. 65, 4661-4667 (1997).
116. Earnhart CG, Buckles EL, Dumler JS, Marconi RT: Demonstration of OspC type diversity in invasive human Lyme disease isolates and identification of previously uncharacterized epitopes that define the specificity of the OspC murine antibody response. Infect. Immun. 73, 7869-7877 (2005).
117. Earnhart CG, Buckles EL, Marconi RT: Development of an OspC-based tetravalent, recombinant, chimeric vaccinogen that elicits bactericidal antibody against diverse Lyme disease spirochete strains. Vaccine 25, 466-480 (2007).
118. Earnhart CG, Marconi RT: An octavalent Lyme disease vaccine induces antibodies that recognize all incorporated OspC type-specific sequences. Hum. Vaccin. 3, 281-289 (2007).
119. Jobe DA, Lovrich SD, Schell RF, Callister SM: C-terminal region of outer surface protein C binds borreliacidal antibodies in sera from patients with Lyme disease. Clin. Diagn. Lab. Immunol. 10, 573-578 (2003).
120. Lovrich SD, Jobe DA, Schell RF, Callister SM: Borreliacidal OspC antibodies specific for a highly conserved epitope are immunodominant in human Lyme disease and do not occur in mice or hamsters. Clin. Diagn. Lab. Immunol. 12, 746-751 (2005).
121. Lovrich SD, LaFleur RL, Jobe DA et al.: Borreliacidal OspC antibody response of canines with Lyme disease differs significantly from that of humans with Lyme disease. Clin. Vaccine Immunol. 14, 635-637 (2007).
122. LaFleur RL, Dant JC, Wasmoen TL et al.: Bacterin that induces OspA and OspC borreliacidal antibodies provides a high level of protection against canine Lyme disease. Clin. Vaccine Immunol. 16, 253-259 (2009).
123. Nowalk AJ, Gilmore RD Jr, Carroll JA: Serologic proteome analysis of Borrelia burgdorferi membrane-associated proteins. Infect. Immun. 74, 3864-3873 (2006).
124. McDowell JV, Hovis KM, Zhang H, Tran E, Lankford J, Marconi RT: Evidence that the BBA 68 protein (BbCRASP-1) of the Lyme disease spirochetes does not contribute to factor H-mediated immune evasion in humans and other animals. Infect. Immun. 74, 3030-3034 (2006).
125. de la Fuente J, Kocan KM, Almazan C, Blouin EF: Targeting the tick-pathogen interface for novel control strategies. Front Biosci. 13, 6947-6956 (2008).